## LEN: Lennar Corporation - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_20 -12.4% below STRENGTH zone (4.0-10.0%); PEG 1.98 fails VALUE criteria (<1.0); RSI 29 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio? - ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN)**
- Source: Benzinga | 20251222T111045 | Bearish | Relevance: 85%
- This article identifies the top ten large-cap stock losers from the week of December 15-19, 2025, including Nike, Arm Holdings, and Insmed. Reasons for their declines range from earnings misses and analyst downgrades to issues with clinical trials and broader market volatility. Investors are prompted to check if any of these underperforming stocks are part of their current portfolio.

**2. KB Home (KBH): Reassessing Valuation After Strong Earnings But Cautious 2026 Outlook**
- Source: Simply Wall Street | 20251221T210933 | Neutral | Relevance: 64%
- KB Home (KBH) delivered mixed results, beating earnings and revenue expectations but offering a cautious 2026 outlook due to affordability pressures and a thinner backlog. This led to an 8.5% share price decline, raising questions about whether it's an undervalued opportunity or if the market is correctly pricing in slower growth. While a "narrative fair value" suggests the stock is 15.6% undervalued, a Discounted Cash Flow model indicates it's overvalued at current prices.

**3. Major Sale Marks Toll Brothers’ Exit From Apartment Business**
- Source: BUCKSCO.Today | 20251220T150924 | Neutral | Relevance: 62%
- Fort Washington's Toll Brothers has sold an Atlanta apartment tower for $132 million, signaling its exit from the multifamily business. This strategic move allows the company to refocus on luxury homebuilding, with the broader transaction of selling Toll Brothers Apartment Living to Kennedy Wilson valued at $347 million. The divestment aims to unlock capital for shareholders and streamline operations.

**4. Green Brick Partners (GRBK): Revisiting Valuation After a Strong Multi‑Year Share Price Run**
- Source: Simply Wall Street | 20251220T020924 | Neutral | Relevance: 55%
- Green Brick Partners (GRBK) has seen significant share price appreciation, outperforming many peers, though a recent pullback has occurred. Trading at $65.44, it's considered 5.5% overvalued compared to a narrative fair value of $62.00, with analysts expecting a dip in future earnings. However, strong performance in key markets and industry-leading margins could challenge this cautious valuation.

**5. Form DEF 14A BEAZER HOMES USA INC For: Sep 30**
- Source: StreetInsider | 20251222T131029 | Neutral | Relevance: 53%
- BEAZER HOMES USA INC. has filed its DEF 14A form for the period ending September 30, detailing proposals for the upcoming annual meeting on February 5, 2026. Key proposals include the election of directors, an advisory vote on executive compensation, ratification of Deloitte & Touche LLP as independent auditors, and the adoption and ratification of protective measures related to NOLs and Energy-Efficiency Tax Credits. The company also reported its financial and operational achievements for fiscal year 2025, highlighting its continued progress towards multi-year goals, including increased community count and achieving its Zero Energy Ready home goal.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 1, Lowers: 9)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $80 | $115 | -30% |
| 2025-12-18 | Barclays | $88 | $98 | -10% |
| 2025-12-18 | UBS | $137 | $161 | -15% |
| 2025-12-18 | Wells Fargo | $110 | $125 | -12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Underweight |
| 2025-12-18 | Barclays | main | Underweight |
| 2025-12-18 | UBS | main | Buy |
| 2025-12-18 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-4.7%)
- Blackrock Inc.: 9.5% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+121.1%)
- State Street Corpora: 4.7% (-3.1%)
- Greenhaven Associate: 4.3% (+1.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.9% 5d) with bearish MACD, trend may be turning.
2. High short interest (22.4%, 4.5 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 9.5% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.98 elevated, pricing in significant growth expectations. Forward P/E 10.6x attractive for 37% earnings growth. Balance sheet: strong liquidity (4.9x). Analyst sentiment negative (9 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.4B |
| Beta | 1.40 |
| 52W Range | $98.42 - $144.24 |
| Short Interest | 22.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.98 |
| Forward P/E | 10.6 |
| Current P/E | 14.5 |
| YoY Growth | 37.0% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -4.5% to -12.4% (-7.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 16.4pp (needs >4.0% for momentum thesis). AM_20 at -11.9% indicates price below own 20MA trend. Underperforming sector by 14.2pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram bearish (-1.84), momentum weakening. RSI oversold at 29, potential bounce setup. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -12.43% (CS: 1) | Weak |
| RSI_14 | 29.0 | Oversold |
| MACD Histogram | -1.84 | Bearish |
| vs SMA20 | 0.881x | Below |
| vs SMA50 | 0.875x | Below |
| vs SMA200 | 0.905x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $107.00
- **Stop Loss:** $99.32 (7.2% risk)
- **Target:** $114.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $12,519.00
- **Portfolio %:** 12.52%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.18 | $2.03 | -6.8% |
| 2025Q3 | $2.09 | $2.00 | -4.5% |
| 2025Q2 | $1.94 | $1.90 | -2.0% |
| 2025Q1 | $1.71 | $2.14 | +24.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*